Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 229

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker

Open access
Carvalho, Kátia C, Cunha, Isabela W, Rocha, Rafael M, Ayala, Fernanda R, Cajaíba, Mariana M, Begnami, Maria D, Vilela, Rafael S, Paiva, Geise R, Andrade, Rodrigo G, Soares, Fernando A·2011·Clinics

Abstract

OBJECTIVE: To analyze glucose transporter 1 expression patterns in malignant tumors of various cell types and evaluate their diagnostic value by immunohistochemistry. INTRODUCTION: Glucose is the major source of energy for cells, and glucose transporter 1 is the most common glucose transporter in humans. Glucose transporter 1 is aberrantly expressed in several tumor types. Studies have implicated glucose transporter 1 expression as a prognostic and diagnostic marker in tumors, primarily in conjunction with positron emission tomography scan data. METHODS: Immunohistochemistry for glucose transporter 1 was performed in tissue microarray slides, comprising 1955 samples of malignant neoplasm from different cell types. RESULTS: Sarcomas, lymphomas, melanomas and hepatoblastomas did not express glucose transporter 1. Forty-seven per cent of prostate adenocarcinomas were positive, as were 29% of thyroid, 10% of gastric and 5% of breast adenocarcinomas. Thirty-six per cent of squamous cell carcinomas of the head and neck were positive, as were 42% of uterine cervix squamous cell carcinomas. Glioblastomas and retinoblastomas showed membranous glucose transporter 1 staining in 18.6% and 9.4% of all cases, respectively. Squamous cell carcinomas displayed membranous expression, whereas adenocarcinomas showed cytoplasmic glucose transporter 1 expression. CONCLUSION: Glucose transporter 1 showed variable expression in various tumor types. Its absence in sarcomas, melanomas, hepatoblastomas and lymphomas suggests that other glucose transporters mediate the glycolytic pathway in these tumors. The data suggest that glucose transporter 1 is a valuable immunohistochemical marker that can be used to identify patients for evaluation by positron emission tomography scan. The function of cytoplasmic glucose transporter 1 in adenocarcinomas must be further examined.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1590/s1807-59322011000600008

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 229

Metadata

Authors
Carvalho, K. C., Cunha, I. W., Rocha, R. M., Ayala, F. R., Cajaíba, M. M., Begnami, M. D., Vilela, R. S., Paiva, G. R., Andrade, R. G., & Soares, F. A.
Venue
Clinics
Publisher
Elsevier BV
Published
2011-06
Volume
66
Issue
6
Pages
965-972
ISSN
1807-5932 (ISSN-L)
OpenAlex
W2132734779
Cited by
229
References
3
FWCI
2.16
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. https://app.cochat.ai/papers/10.1590/s1807-59322011000600008
The paper
Carvalho, K. C., Cunha, I. W., Rocha, R. M., Ayala, F. R., Cajaíba, M. M., Begnami, M. D., Vilela, R. S., Paiva, G. R., Andrade, R. G., & Soares, F. A. (2011). GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics. https://doi.org/10.1590/s1807-59322011000600008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.